Sarepta Setback: FDA Doubts About DMD Biomarker Crushes Early Approval Dreams
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s rejection of dystrophin as a biomarker in Duchenne muscular dystrophy and doubts about the six-minute walk test endpoint put Sarepta back at square one.